La Jolla Institute for Immunology
A groundbreaking new HIV vaccine has shown unprecedented success in primates—and data published in Nature suggest the vaccine has the potential to protect humans from developing HIV infection and AIDS.
The vaccine was developed through a 14-year collaboration led by scientists at La Jolla Institute for Immunology (LJI) and Scripps Research. "This has been one of those Apollo moon mission-type projects, where there is an exceptional goal and the team has to accomplish a myriad of discoveries and inventions along the way," says LJI Professor and Chief Scientific Officer Shane Crotty, Ph.D. , who co-led the research with Scripps Research Professor William Schief, Ph.D.
Highlights:
- The researchers developed an HIV vaccine that trains immune cells to see past HIV's defenses.
- The new HIV vaccine works by prompting the body's immune system to make high numbers of rarely seen "broadly neutralizing" antibodies.
- In a recent pre-clinical trial, this vaccine resulted in the best HIV-fighting antibody response ever seen in primates.
- The research suggests the new vaccine has the potential to protect humans from developing HIV infection and AIDS.
Media resources:
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
